3. Biohaven Ltd. (NYSE:BHVN)
Biohaven Ltd. is the more speculative name in this biotech list, but that is exactly why it can be interesting for aggressive investors looking for high-risk, high-reward healthcare stocks. Based on the provided May 10, 2026 data, Biohaven was priced at $9.86, with a 12-week price change of -13.20%, no listed forward P/E, and projected one-year EPS growth of 56.64%. The stock’s negative recent performance tells investors that the market is still cautious, but the projected EPS improvement and pipeline-heavy setup suggest that sentiment could change quickly if clinical milestones arrive favorably.
Biohaven is a clinical-stage biopharmaceutical company, which means its story is not centered on current product sales. Instead, the investment case depends heavily on pipeline execution, clinical data, capital discipline, and the company’s ability to advance promising programs without burning through cash too quickly. This is a very different kind of biotech stock compared with commercial-stage names. It carries more uncertainty, but it can also move sharply when trial results, regulatory updates, or partnership developments surprise the market.
The company’s first-quarter 2026 report highlighted several upcoming milestones. Biohaven said it expects initial topline results in the second half of 2026 from the first of two Phase 2/3 studies of opakalim in focal epilepsy. It also completed enrollment in a Phase 2 obesity study for taldefgrobep alfa during the first quarter of 2026, with topline results expected in the second half of the year. In addition, pivotal study initiation for BHV-1400 in IgA nephropathy and BHV-1300 in Graves’ disease is expected around mid-2026.
That pipeline matters because Biohaven is not betting on only one shot. Its programs span neurological disease, obesity, immunology, kidney disease, and thyroid-related autoimmune disease. For biotech investors, multiple data readouts can create multiple potential catalysts. But the risk is also multiplied. If key data disappoints, the stock can suffer quickly because clinical-stage companies often depend heavily on investor confidence in future outcomes.
Financially, Biohaven is trying to show better discipline. The company reported cash, cash equivalents, marketable securities, and restricted cash of approximately $351.8 million as of March 31, 2026. Research and development expenses fell to $103.8 million for the first quarter of 2026 from $187.6 million in the same period of 2025, mainly due to lower direct program and preclinical spending after strategic reprioritization. General and administrative expenses also declined to $26.6 million from $34.0 million year over year.
The net loss also narrowed. Biohaven reported a first-quarter 2026 net loss of $130.5 million, or $0.88 per share, compared with a net loss of $221.7 million, or $2.17 per share, in the same period of 2025. On a non-GAAP basis, adjusted net loss improved to $102.2 million, or $0.69 per share, compared with $166.8 million, or $1.64 per share, in the prior-year period.
The company said it is positioned for “value-creating milestones” in 2026, and that phrase is the heart of the Biohaven investment case. This is not a quiet, low-volatility biotech stock. It is a catalyst-driven biotech name where the market is likely to watch trial timelines, cash usage, R&D spending, and clinical updates very closely.
For investors searching for clinical-stage biotech stocks, biotech stocks with high upside potential, rare disease biotech stocks, epilepsy drug stocks, and obesity treatment stocks, Biohaven belongs on the watchlist. But this is also the name where caution matters most. It has no listed forward P/E in the provided data, and its value depends heavily on future clinical success. In simple terms, Biohaven could become a powerful turnaround story if its pipeline delivers, but it remains a higher-risk bet than more established biotech companies.
Click next to see the following stock...
